📊 BRGX Key Takeaways
Is Bioregenx, Inc.. (BRGX) a Good Investment?
BioRegenx is a financially distressed company with negative stockholders' equity of -$3.6M, liabilities exceeding assets by over 4x, and severe liquidity constraints (current ratio of 0.07x). Despite a healthy 80.7% gross margin, the company is unprofitable at the operating level (-21% margin) and burning cash with negative operating and free cash flows, indicating fundamental business model challenges beyond cost of goods sold.
BIOREGENX shows attractive gross profitability, but that strength is overwhelmed by weak operating execution, persistent net losses, and a severely distressed balance sheet. With just $46.95K of cash, negative free cash flow, a 0.07x current ratio, and negative equity of $3.65M, the company appears financially fragile and dependent on external funding or balance sheet restructuring to remain viable.
Why Buy Bioregenx, Inc.. Stock? BRGX Key Strengths
- High gross margin of 80.7% suggests strong product pricing power or efficient production
- Small revenue base of $1.5M provides potential runway if business can stabilize
- Service sector positioning in computer programming may have growth potential if company survives
- High gross margin of 80.7%, indicating potentially attractive unit economics before overhead and financing costs
- Revenue base of $1.47M with gross profit of $1.18M, showing the business can generate meaningful gross profit relative to sales
- Operating cash burn is modest relative to revenue, suggesting losses are not yet driven by extreme cash outflows
BRGX Stock Risks: Bioregenx, Inc.. Investment Risks
- Negative stockholders' equity of -$3.6M indicates technical insolvency and high bankruptcy risk
- Critical liquidity crisis with current ratio of 0.07x and only $46.9K cash against $4.8M liabilities
- Negative operating cash flow of -$30.7K and free cash flow of -$36.7K show unsustainable burn rate
- Operating losses of -$308.3K on $1.5M revenue demonstrate inability to scale profitably
- High long-term debt of $1.1M with negative interest coverage of -1.4x raises default risk
- Severe liquidity stress, with only $46.95K in cash and a 0.07x current ratio
- Negative stockholders' equity of $3.65M and liabilities of $4.81M versus just $1.17M in assets
- Unprofitable operations and weak debt service capacity, with negative operating margin and interest coverage of -1.4x
Key Metrics to Watch
- Stockholders' equity trend - any movement toward positive equity would signal turnaround
- Operating cash flow - must reach breakeven to demonstrate business sustainability
- Total liabilities vs total assets - current 4:1 ratio is critical distress indicator
- Quarterly revenue growth - needed to justify continued operations
- Cash runway - with current burn rate, assess months of remaining liquidity
- Cash balance and current ratio improvement
- Operating income and free cash flow trend
Bioregenx, Inc.. (BRGX) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
BRGX Profit Margin, ROE & Profitability Analysis
BRGX vs Technology Sector: How Bioregenx, Inc.. Compares
How Bioregenx, Inc.. compares to Technology sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Bioregenx, Inc.. Stock Overvalued? BRGX Valuation Analysis 2026
Based on fundamental analysis, Bioregenx, Inc.. has mixed fundamental signals relative to the Technology sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Bioregenx, Inc.. Balance Sheet: BRGX Debt, Cash & Liquidity
BRGX Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Bioregenx, Inc..'s revenue has grown significantly by 1,078% over the 5-year period, indicating strong business expansion. The most recent EPS of $-0.03 indicates the company is currently unprofitable.
BRGX Revenue Growth, EPS Growth & YoY Performance
BRGX Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $507.8K | -$80.6K | $0.00 |
| Q2 2025 | $446.0K | -$178.3K | $0.00 |
| Q1 2025 | $515.1K | -$266.9K | $0.00 |
| Q3 2024 | $596.0K | -$394.9K | $0.00 |
| Q2 2024 | $734.0K | -$594.5K | $0.00 |
| Q3 2023 | $3.7K | -$2.2K | $0.00 |
| Q2 2023 | $7.9K | -$4.1K | $0.00 |
| Q1 2023 | $5.6K | -$37.3K | $0.00 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Bioregenx, Inc.. Dividends, Buybacks & Capital Allocation
BRGX SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Bioregenx, Inc.. (CIK: 0001593184)
📋 Recent SEC Filings
❓ Frequently Asked Questions about BRGX
What is the AI rating for BRGX?
Bioregenx, Inc.. (BRGX) has a Combined AI Rating of STRONG SELL from Claude (STRONG SELL) and ChatGPT (STRONG SELL) with 94% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are BRGX's key strengths?
Claude: High gross margin of 80.7% suggests strong product pricing power or efficient production. Small revenue base of $1.5M provides potential runway if business can stabilize. ChatGPT: High gross margin of 80.7%, indicating potentially attractive unit economics before overhead and financing costs. Revenue base of $1.47M with gross profit of $1.18M, showing the business can generate meaningful gross profit relative to sales.
What are the risks of investing in BRGX?
Claude: Negative stockholders' equity of -$3.6M indicates technical insolvency and high bankruptcy risk. Critical liquidity crisis with current ratio of 0.07x and only $46.9K cash against $4.8M liabilities. ChatGPT: Severe liquidity stress, with only $46.95K in cash and a 0.07x current ratio. Negative stockholders' equity of $3.65M and liabilities of $4.81M versus just $1.17M in assets.
What is BRGX's revenue and growth?
Bioregenx, Inc.. reported revenue of $1.5M.
Does BRGX pay dividends?
Bioregenx, Inc.. does not currently pay dividends.
Where can I find BRGX SEC filings?
Official SEC filings for Bioregenx, Inc.. (CIK: 0001593184) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is BRGX's EPS?
Bioregenx, Inc.. has a diluted EPS of $0.00.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is BRGX a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Bioregenx, Inc.. has a STRONG SELL rating with 94% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is BRGX stock overvalued or undervalued?
Valuation metrics for BRGX: ROE of N/A (sector avg: 22%), net margin of -35.8% (sector avg: 18%). Compare these metrics with sector averages to assess valuation.
Should I buy BRGX stock in 2026?
Our dual AI analysis gives Bioregenx, Inc.. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is BRGX's free cash flow?
Bioregenx, Inc..'s operating cash flow is $-30.7K, with capital expenditures of $6.0K. FCF margin is -2.5%.
How does BRGX compare to other Technology stocks?
Vs Technology sector averages: Net margin -35.8% (avg: 18%), ROE N/A (avg: 22%), current ratio 0.07 (avg: 2.5).